Par appoints new president, COO
WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has promoted Thomas Haughey to president and Paul Campanelli to COO, the company said. The promotions take effect immediately.
"With the acquisition of Anchen and the pending acquisition of Edict, Par is becoming a larger and more complex organization with three diverse locations and more than 300 additional employees," Par chairman and CEO Patrick LePore said. "These new challenges and opportunities require a president and COO to effectively manage the company and its subsidiaries."
Haughey has served as chief administrative officer since 2008, previously serving as general counsel and secretary, from 2003 to 2006, and as EVP from 2006 to 2008. Campanelli will retain his title of president of Par Pharmaceutical, the company’s generics division, while also assuming responsibility for Strativa Pharmaceuticals, its branded division. Campanelli began working at Par in 2001 as senior director for business development.
BioPlus now offering e-prescribing
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy announced that it now is allowing physicians to electronically submit prescriptions to its pharmacies.
BioPlus said its e-prescribing offering is designed to lessen the risk of errors, lower costs and improve compliance. The use of computerized medication order entry potentially could prevent up to 84% of dose, frequency and route errors in medication use, according to data from the Agency for Healthcare Research and Quality,a Department of Health and Human Services agency.
“Electronic prescriptions were the next step in our Quality Improvement Program, not only ensuring prescription accuracy and security of patient data, but also increasing efficiencies in our clinical departments allowing us to further focus on our key objective – measurably improving patient outcomes,” BioPlus director of technology and operations Eric Jackson said.
Pfizer acquiring Excaliard Pharmaceuticals
NEW YORK — Pfizer will acquire a San Diego-based drug maker focused on treatments for skin scarring, the company said Tuesday.
Pfizer said it would buy privately owned Excaliard Pharmaceuticals, whose lead product, EXC 001, is in phase-2 trials for skin scarring, also known as skin fibrosis, a result of surgical procedures. There currently are no Food and Drug Administration-approved treatments to reduce scar severity. Financial terms of the deal were not disclosed.
"The acquisition of Excaliard is part of our corporate research and development strategy to actively complement our robust internal project pipeline with innovative and differentiated drugs from biotech partners," Pfizer president for worldwide research and development Mikael Dolsten said.